Newly diagnosed oestrogen receptor-positive breast cancers are commonly treated with drugs that interrupt oestrogenic stimulation of cell growth: classically tamoxifen and more recently the aromatase inhibitors. However, tamoxifen treatment is limited by the development of resistance and disease relapse ([@bib6]). Endocrine resistance is often associated with enhanced expression of members of the ErbB receptor family, especially EGFR and ErbB2, and activation of the AKT ([@bib13]) and MAPK ([@bib11]) ErbB2/3 downstream signal transduction pathways. A further understanding of the role that ErbB receptors has in development of hormone resistance is important, as approximately half of breast cancers that overexpress ErbB2 also express hormone receptors ([@bib20]).

Activation of the ErbB2-stimulated serine/threonine kinase P21-activated kinase 1 (PAK1) leads to the development of tamoxifen resistance. P21-activated kinase 1 is phosphorylated and activated by Rac and AKT in breast cancer cells after treatment with the ErbB3/4 ligand heregulin (HRG) ([@bib26]). Activation of PAK1 inhibits tamoxifen action *in vitro* and in animal models ([@bib21]). P21-activated kinase 1-induced tamoxifen resistance has been linked to its phosphorylation of ER*α* at S305 ([@bib21]). Clinically, the nuclear localisation of PAK1 is associated with tamoxifen resistance in a subset of ER-positive tumours ([@bib9]). P21-activated kinase 1 gene and protein amplification is also a predictor of recurrence and tamoxifen resistance in postmenopausal breast cancer ([@bib4], [@bib5]; [@bib12]). P21-activated kinase 1 was recently identified as an oncogene that activates the MAPK pathway and c-MET in breast cancer ([@bib24]). Inhibition of PAK1 by shRNA in breast cancer cells results in apoptosis and downregulation of E2F1-regulated genes ([@bib18]).

The biological activity and expression of ErbB2 and ErbB3 are regulated by a host of interacting proteins that may be potential targets for development of new therapies for treatment of hormone resistance. An ErbB3-binding protein (EBP1) was isolated in our laboratory during a yeast two-hybrid screen for ErbB3-interacting proteins ([@bib30]). Overexpression of *EBP1* inhibits growth of ErbB2/3 expressing breast cancer cell lines, promotes G2/M cell cycle arrest and cellular differentiation ([@bib14]), and inhibits AKT activation and cell proliferation in response to HRG ([@bib32]). The biological activity of EBP1 is regulated by the kinases PKC*δ* ([@bib1]; [@bib15]) and PAK1 ([@bib2]). Phosphorylation of EBP1 at S360 by PKC*δ* ([@bib1]) and T261 by PAK1 ([@bib2]) has been demonstrated *in vitro* and *in vivo* ([@bib2]).

Recent work from our laboratory indicates a role for EBP1 in modulating hormone sensitivity. Overexpression of *EBP1* results in an increase in tamoxifen sensitivity in hormone sensitive cells ([@bib2]) and a decrease in ErbB2 protein levels ([@bib32]). Silencing of EBP1 results in the increased expression of ErbB2 in tamoxifen sensitive MCF-7 ([@bib32]) and T47D cells ([@bib16]), and the development of tamoxifen resistance. This tamoxifen resistance is overcome by HER-2 kinase inhibitors ([@bib16]), suggesting that EBP1\'s effect on tamoxifen sensitivity may be mediated by its ability to modulate ErbB2 expression. Transfection of an *EBP1* mutant, which mimics PAK1-induced phosphorylation at T261 induces tamoxifen resistance in MCF-7 cells.

As our previous work only examined hormone sensitive cells, we sought to determine if PAK1\'s interactions with EBP1 might affect ErbB2 levels and the response to tamoxifen in hormone resistant cells. We found that a T261E *EBP1* PAK1 phosphomimetic mutant increased ErbB2 levels. An *EBP1* T261A mutant that was unable to be phosphorylated by PAK1 reversed PAK1-induced tamoxifen resistance. Pharmacological reduction of PAK1 activity by IPA-3 in hormone resistant LTLT-Ca cells, in which both PAK1 and ErbB2 are endogenously overexpressed, inhibited cell growth, but did not induce tamoxifen sensitivity. However, IPA-3 sensitised LTLT-Ca cells to tamoxifen when *EBP1* was overexpressed. IPA-3 decreased ErbB2 levels only when *EBP1* was overexpressed. These studies suggest that phosphorylation of EBP1 may be one mechanism of PAK1-induced hormone resistance and that PAK1 inhibitors may be useful in cells in which EBP1 is overexpressed.

Materials and methods
=====================

Cell culture
------------

MCF-7 and AU565 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). T47D cells were a gift of Dr Stuart Martin, University of Maryland School of Medicine. All cell lines were maintained at 37 °C in a humidified atmosphere of 5% CO~2~ in air in RPMI 1640 (Biofluids, Rockville, MD, USA) and 10% FBS (Sigma, St Louis, MO, USA). LTLT-Ca cells were a gift of Dr Angela Brodie, University of Maryland School of Medicine and maintained as described ([@bib11]). LTLT-Ca cells were derived from aromatase-transfected MCF-7 cells made tamoxifen resistant by passage *in vivo* in the presence of letrozole ([@bib22]).

Reagents
--------

Heregulin *β*1 (HRG*β*1) was obtained from R & D Systems Inc. (Minneapolis, MN, USA), 4-hydroxy-tamoxifen (OHT) and 17 β-estradiol from Sigma.

Plasmids
--------

A full-length *EBP1* cDNA (GenBank NM006191) was generated by PCR with specific reverse and forward primers containing *XhoI* and *BamH*I restriction sites using a pcDNA-*EBP*1 vector as a template ([@bib28]). This cDNA includes all three possible translation initiation sites of *EBP1* and encodes the largest form of the protein ([@bib29]). The hygromycin resistant wild-type *EBP1* plasmid was constructed by cloning this full-length *EBP1* into the *XhoI* and *BamH1* sites of the pAGFP1-Hyg-C1 vector (Clontech, Palo Alto CA, USA). The *EBP1* T261A expression plasmid was constructed in pcDNA3 Hygro (Invitrogen, Carlsbad, CA, USA) with a GFP tag. The orientation and integrity of cDNA inserts in the newly constructed plasmids were confirmed by automated DNA sequencing in the core laboratory of the University of Maryland School of Medicine. Constitutively active *PAK1* (T423E) cloned into pcDNA3 was a gift of Dr Z Luo ([@bib31]).

Creation of stably transfected cell lines
-----------------------------------------

To establish LTLT-Ca-overexpressing *EBP1* stable transfectants, subconfluent cells in 100-mm tissue culture dishes were transfected with 10 *μ*g of pAGFP1-Hyg-C1 or pAGFP1-Hyg-C1-*EBP1* or pcDNA-GFP-Hyg or pcDNA-GFP-Hyg-*EBP1* T261A expression plasmids using Fugene-6 (Roche, Indianapolis, IN, USA) according to the manufacturer\'s protocol. Cells were selected in hygromycin (20 *μ*g ml^−1^) for 4 weeks and mass cultures obtained. Cells were further selected for high GFP--*EBP1* expression by FACS sorting. MCF-7 cells stably expressing a constitutively active *PAK1* (T423E) were made by transfecting cells as described above with the pcDNA3 vector expressing *PAK1* T423E. Cells were selected in 500 *μ*g ml^−1^ of G418. The T47D EBP1-silenced cell line and the BT474-*EBP1*-overexpressing cell line have been previously described ([@bib16]).

Western blot assay
------------------

Total cell lysates were prepared by direct lysis with HNTG buffer (50 mℳ HEPES pH 7.5, 150 mℳ NaCl, 1.5 mℳ MgCl~2~, 0.01% Triton X100, 10% glycerol). Protein concentrations were determined using the Bio-Rad detergent compatible protein assay kit (Bio-Rad, Hercules, CA, USA). The samples were mixed with Nupage sample buffer and resolved by denaturing NuPAGE. Proteins were transferred to PVDF membranes and immunoblotted with the appropriate primary and secondary antibodies. An ECL detection kit (Pierce, Rockford, IL, USA) was used to visualise the bands. Where indicated, images were quantified using IMAGE-J software (NIH, Bethesda, MD, USA).

Antibodies
----------

Primary antibodies included those directed against EBP1 (rabbit, Millipore, Billerica, MA, USA), GFP (mouse, Clontech), GAPDH, p-threonine, PAK1 and phospho-PAK (T423) (rabbit, Cell Signaling, Danvers, MA, USA), tubulin and Actin (rabbit, Sigma). Secondary antibodies included goat anti-rabbit HRP (Bio-Rad) and sheep anti-mouse HRP (Amersham, Piscataway NJ, USA).

Immunoprecipitation
-------------------

EBP1 was immunoprecipitated from MCF-7 and LTLT-Ca cell lysates using anti-EBP1 antibody as previously described ([@bib2]). The immunoprecipitated proteins were resolved by SDS--PAGE and analysed by western blotting using anti phospho-threonine (Cell Signaling) or EBP1 primary antibodies and a peroxidase-conjugated mouse anti-rabbit conformation-specific secondary antibody (Cell Signaling).

Cell growth assays
------------------

For studies assessing the effect of tamoxifen on cell growth, cells (2 × 10^3^) were plated in 96-well plates in complete media. After a 24-hour attachment period, the medium was replaced with medium containing 2% FBS and 10^−8^ ℳ 17-*β* estradiol and OHT with or without IPA-3 at the indicated concentrations. Cells were refed at day 4. Relative live cell numbers were determined at day 7 using a Promega proliferation reagent (Promega, Madison, WI, USA) as per the manufacturer\'s instructions with absorbance being read at 490 nm using a Thermo Multiskan Ascent plate reader (Thermo Scientific, Hudson, NH, USA).

Statistical analysis
--------------------

Data were analysed using a two-tailed Student\'s *t*-test. Differences with a *P*\<0.05 were deemed significant.

Results
=======

Effect of an *EBP1* T261E mutant on ErbB2 levels
------------------------------------------------

We previously demonstrated that PAK1 phosphorylated EBP1 *in vitro* at T261 and that a phosphomimetic T261E mutant induced tamoxifen resistance in hormone sensitive MCF-7 cells ([@bib2]). As the ability of EBP1 to decrease ErbB2 levels has a role in its induction of tamoxifen sensitivity ([@bib16]), we tested the effect of an *EBP1* T261E phosphomimetic on ErbB2 levels. We used AU565 cells, which exhibit a large decrease in ErbB2 levels after ectopic expression of EBP1 ([@bib32]) ([@bib16]). Transient transfection of wild-type *EBP1* decreased ErbB2 protein as expected. However, a phosphomimetic T261E *EBP1* increased ErbB2 levels ([Figure1](#fig1){ref-type="fig"}). We ([@bib2]) and others ([@bib25]) have demonstrated the subcellular localisation of the GFP-tagged proteins is identical to that of the endogenous protein. The GFP--EBP1 fusion proteins were expressed at approximately equal levels ([Figure 1](#fig1){ref-type="fig"}). This finding suggests that phosphorylation of the T261 site abrogates the ability of EBP1 to decrease ErbB2 protein levels.

An *EBP1* T261A mutant reduces PAK1-induced tamoxifen resistance
----------------------------------------------------------------

PAK1 has been demonstrated to induce tamoxifen resistance via phosphorylation of ER*α* ([@bib21]). We postulated that EBP1 phosphorylation by PAK1 and the subsequent inhibition of EBP1\'s ability to reduce ErbB2 levels might also have a role in tamoxifen resistance. We, therefore, tested if an *EBP1* T261A mutant that could not be phosphorylated by PAK1 could overcome PAK1-induced tamoxifen resistance. We created MCF-7 cells stably transfected with a constitutively activated *PAK1* T423E ([Figure 2A](#fig2){ref-type="fig"}). PAK1 levels were increased in these cells as expected. In addition, ErbB2 levels were increased ([Figure 2A](#fig2){ref-type="fig"}). We have previously published that EBP1 Thr phosphorylation is increased in MCF-7 cells transfected with *PAK1* ([@bib2]). As expected, overexpression of a constitutively active *PAK1* resulted in tamoxifen resistance ([Figure 2B](#fig2){ref-type="fig"}). We next transiently transfected these tamoxifen resistant *PAK1* T423E MCF-7 stable transfectants with GFP vector control, wild-type *EBP1, T261A* or *T261E EBP1* mutants and assessed tamoxifen sensitivity. Transfection of the *EBP1* T261A mutant was able to partially overcome PAK1-mediated tamoxifen resistance. In keeping with previous data using parental MCF-7 cells ([@bib2]), transfection of a wild-type *EBP1* increased tamoxifen sensitivity, but not as much as the T261A mutant. The *EBP1* T261E mutant increased resistance at low concentrations of tamoxifen ([Figure 2C](#fig2){ref-type="fig"}). Equal expression levels of the EBP1 fusion proteins were observed ([Figure 2C](#fig2){ref-type="fig"}).

P21-activated kinase 1 inhibitors reverse tamoxifen resistance only when *EBP1* is overexpressed
------------------------------------------------------------------------------------------------

We next tested the hypothesis that PAK1 inhibitors, by reducing PAK1 phosphorylation of EBP1, could reverse tamoxifen resistance. We used the LTLT-Ca cell line, made hormone resistant by *in vivo* passage in the presence of letrozole. This cell line endogenously overexpresses ErbB2 ([@bib11]). We found that this cell line also overexpresses PAK1 as compared with parental MCF-7 cells and that PAK1 is constitutively phosphorylated ([Figure 3A](#fig3){ref-type="fig"}). In keeping with the fact that PAK1 is overexpressed, basal threonine phosphorylation of EBP1 was observed in LTLT-Ca cells. No specific threonine phosphorylation of EBP1 was observed in MCF-7 parental cells ([Figure 3B](#fig3){ref-type="fig"}) as previously reported ([@bib2]).

We tested the effects of IPA-3, a PAK1 inhibitor that interferes with PAK1 activation by altering PAK conformation and potentially blocking opening of the autoinibited state ([@bib7]; [@bib27]), on the tamoxifen sensitivity of this line. As little is known about the effects of IPA-3 on proliferation of hormone resistant breast cancer cells, we first tested the response LTLT-Ca cells to IPA-3. Dose--response curves indicated that 3 *μ*ℳ IPA-3 inhibited cell proliferation by ∼20% ([Figure 3C](#fig3){ref-type="fig"}). As we were interested in using IPA-3 at a 20% growth-inhibitory dose for further combination studies with tamoxifen, we examined its effect on PAK activation at this dose. IPA-3 reduced HRG-induced phosphorylation in serum-starved cells at this concentration by ∼50% as indicated by densitometric analysis of western blots ([Figure 3D](#fig3){ref-type="fig"}). Higher non-toxic concentrations (5 and 10 *μ*ℳ) did not further inhibit phosphorylation under these conditions (data not shown). We next tested the effects of a combination of OHT and IPA-3 on cell growth. As has been reported ([@bib23]; [@bib22]), OHT stimulated the growth of the hormone resistant cell line ([Figure 3E](#fig3){ref-type="fig"}). The tamoxifen-induced growth increase was abrogated by treatment with IPA-3. However, cells did not become sensitive to tamoxifen after IPA-3 treatment ([Figure 3E](#fig3){ref-type="fig"}). Similar results were observed using IC50 doses of IPA (data not shown).

As we demonstrated ([Figure 2](#fig2){ref-type="fig"}) that overexpression of wild-type and T261A mutated *EBP1* ameliorated PAK1-induced tamoxifen resistance, we hypothesised that IPA-3 might be more effective in LTLT-Ca cells when *EBP1* was overexpressed. We reasoned that endogenous PAK1 would be unable to phosphorylate and inactivate a larger pool of EBP1. Thus, inhibition of PAK1 in the presence of high levels of EBP1 might increase active EBP1 levels to a threshold needed to observe EBP1-induced tamoxifen sensitization. Overexpression of *EBP1* had no effect on total PAK levels in LTLT-Ca cells. Surprisingly both basal and HRG-stimulated pPAK levels were elevated in *EBP1* transfectants ([Figure 4A](#fig4){ref-type="fig"}). LTLT-Ca-*EBP1* cells were approximately as sensitive to IPA-3 as vector LTLT-Ca controls (data not shown). Overexpression of *EBP1* sensitised LTLT-Ca cells to tamoxifen ([Figure 4B](#fig4){ref-type="fig"} compared with [Figure 3E](#fig3){ref-type="fig"}) and IPA-3 further enhanced sensitivity to tamoxifen. This sensitization was most markedly observed at lower concentrations of tamoxifen. Growth of *EBP1* wild-type transfectants was inhibited 20% at the highest doses of tamoxifen used compared with controls, but 38% in the presence of IPA as compared with the IPA-3 only treated control. This difference in response between OHT only and OHT-IPA-3-treated groups is statistically significant at *P*\<0.05. In addition, growth of cells in the presence of the highest concentration of OHT and IPA was inhibited 48% compared with untreated controls. These data indicate that overexpression of *EBP1* in combination with partial inhibition of PAK1 activity in LTLT-Ca cells were more effective than either condition alone in sensitising cells to tamoxifen ([Figure 4B](#fig4){ref-type="fig"}).

We were further interested in determining if the effects of IPA-3 on tamoxifen sensitivity might be mediated by PAK1 phosphorylation of EBP1. We, therefore, created LTLT-Ca cells overexpressing *EBP1* T261A, which cannot be phosphorylated by PAK1. Initial growth curves indicated that IPA-3 affected cell growth in approximately the same manner as in LTLC-Ca *EBP1* wild-type transfectants (data not shown). *EBP1* T261A-transfected cells were more sensitive to tamoxifen at low concentrations than *EBP1* wild-type transfectants ( compare [Figure 4B and C](#fig4){ref-type="fig"}) similar to results in [Figure 2](#fig2){ref-type="fig"}. However, IPA-3 did not significantly affect the sensitivity of *EBP1* T261A-transfected cells to tamoxifen as compared with cells treated only with tamoxifen. For example, growth of LTLT-Ca-*EBP1* T261A cells was inhibited 20% at the highest concentration of tamoxifen used and 23% in the presence of IPA-3 compared with IPA only treated cells. This finding suggests that the ability of IPA-3 to sensitise cells to tamoxifen in *EBP1*-overexpressing cells was due in part to its ability to prevent EBP1 phosphorylation. Finally, IPA-3 had no effect on tamoxifen sensitivity in hormone resistant T47D cells in which EBP1 protein expression has been silenced and ErbB2 expression increased ([@bib16]) ([Figure 4D](#fig4){ref-type="fig"}).

As we previously demonstrated that the induction of sensitivity to tamoxifen by EBP1 was related to its effects on ErbB2 levels, we examined ErbB2 levels in both LTLT-Ca vector controls and *EBP1* transfectants. As expected, overexpression of both wild-type and T261A *EBP1* decreased ErbB2 levels in LTLT-Ca cells ([Figure 5A](#fig5){ref-type="fig"}) consistent with the observation that overexpression of *EBP1* sensitised cells to tamoxifen. We next tested the effect of IPA-3 on ErbB2 expression levels in vector control and *EBP1* (wild-type and T261A)-overexpressing cells. IPA-3 decreased ErbB2 levels in both wild-type and mutant *EBP1-*overexpressing cells, but not vector controls ([Figure 5B](#fig5){ref-type="fig"}). IPA-3 was able to inhibit basal phosphorylation of MAPK observed in control LTLT-Ca cells ([@bib11]) and *EBP1*-transfected cells in keeping with previously published data that overexpression of PAK1 activates MAPK signalling pathways ([@bib24]).

Discussion
==========

The clinical importance of ErbB heterodimers and their interacting partners in breast cancer development and endocrine resistance has been well-documented ([@bib10]). However, the role of ErbB-binding proteins in hormone resistance has not been as extensively studied. We have previously shown that the ErbB3-binding protein EBP1 decreases ErbB2 levels and enhances tamoxifen sensitivity of hormone sensitive cells ([@bib2]; [@bib16]). Silencing of EBP1 expression results in increases in ErbB2 levels and development of hormone resistance ([@bib16]). EBP1 is a PAK1 substrate and an *EBP1* T261E mutant, that mimics EBP1 phosphorylated by PAK1, induces tamoxifen resistance in hormone sensitive MCF-7 cells ([@bib2]). We thus postulated that inhibition of PAK1 activity, by restoring EBP1 function, could ameliorate the hormone refractory phenotype of ErbB2-overexpressing breast cancer cells.

As EBP1\'s effect on tamoxifen sensitivity is mediated in part by its ability to modulate ErbB2 expression, we tested if the T261E *EBP1* phosphomimetic mutant could still decrease ErbB2 levels. In keeping with data indicating that this mutant induces tamoxifen resistance ([@bib2]), we found that the phosphomimetic increased ErbB2 protein levels. We postulated that PAK1-induced phosphorylation of EBP1 might represent a previously unrecognised mechanism of PAK1-induced tamoxifen resistance. We, therefore, tested if an *EBP1* T261A mutant that could not be phosphorylated by PAK1 could overcome PAK1-induced tamoxifen resistance. We found that transfection of the *EBP1* T261A mutant could partially reverse PAK-induced tamoxifen resistance. We suggest that phosphorylation of EBP1 may be a novel mechanism of PAK-induced tamoxifen resistance.

We were further interested in determining if inhibition of PAK1 activity could affect sensitivity of hormone resistant cells to tamoxifen, especially as we found for the first time that hormone resistant cells endogenously overexpress PAK1. Results of our proliferation assays indicated that treatment with IPA-3, at a dose which partially inhibits PAK1 phosphorylation, did not sensitise hormone resistant cells to tamoxifen, but did abrogate tamoxifen-induced growth stimulation. The ability of IPA-3 to reverse tamoxifen-induced growth could be due to several factors. PAK1 phosphorylates a large number of substrates that are related to cell growth (Aurora Kinase A, PCBP-1) and apoptosis (Bad, DLC, FKHR) ([@bib8]; [@bib17]), but not specifically endocrine resistance. P21-activated kinase 1 has also been recently demonstrated to be an oncogene in breast cancer via its activation of both MAPK and MET signalling ([@bib24]). It is also possible that complete inhibition of PAK1 activity is needed to observe IPA-3\'s effects on hormone resistance. However, we were unable to completely inhibit PAK1 phosphorylation at doses of IPA-3 that were not non-specifically toxic. This may be due to the fact that a pool of PAK1 is constitutively activated in LTLT-Ca cells and thus would not be subject to inhibition by IPA-3, which acts by blocking opening of auto-inhibited PAK1 dimers.

In contrast, IPA-3 sensitised LTLT-Ca cells to tamoxifen when *EBP1* was overexpressed. We observed similar results in the partially hormone resistant BT474 cell line, which has been shown to have high levels of PAK1 ([@bib18]). This cell line can be sensitised to tamoxifen by *EBP1* overexpresssion. IPA enhances tamoxifen sensitivity in BT474-*EBP1-*overexpressing cells, but not in vector controls cells ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). IPA-3 failed to affect hormone resistance of cells in which EBP1 expression had been silenced. The fact that IPA-3 has no effect on tamoxifen sensitivity in the absence of EBP1 or in the presence of endogenous levels of EBP1 suggests that EBP1 had a role in IPA-3-induced sensitization to tamoxifen in *EBP1*-overexpressing cells. It is possible that the overexpression of *EBP1* provides a large pool of protein that cannot be completely phosphorylated by endogenous PAK1. The reduction of PAK1 activity by IPA-3 may increase the pool of non-phosphorylated EBP1 to a threshold that is needed for its biological activity. In the absence of EBP1 overexpression, IPA-3 inhibition of PAK1 activity is insufficient to allow the pool of non-phosphorylated EBP1 to reach this critical level. The fact that the IPA-3-induced increase in tamoxifen sensitivity was not observed when the *EBP1* T261A mutant was transfected suggests that part of the effect of IPA-3 in the presence of high levels of EBP1 was due to inhibition of PAK1-induced phosphorylation of wild-type overexpressed *EBP1*. The observation that a PAK1 inhibitor may alter sensitivity to tamoxifen in the presence of high levels of EBP1 may have clinical significance as many localised breast cancers overexpress EBP1 ([@bib19]). We are developing a phospho antibody to the EBP1 T261 site for immunohistochemical analysis of clinical breast cancer samples to establish if there is a correlation between PAK1, phospho EBP1 levels and tamoxifen resistance. Such studies are critical to testing our hypothesis that coexpression of PAK1 and phospho EBP1 is associated with tamoxifen resistance in patients.

The molecular downstream events that led to induction of tamoxifen sensitivity by the combination of IPA-3 and *EBP1* overexpression are currently unknown. For example, we found that although *EBP1* (both mutant and wild-type) as expected reduced levels of ErbB2 in LTLT-Ca cells, IPA-3 was able to further reduce ErbB2 levels only in LTLT-Ca-*EBP1* transfectants. ErbB2 levels were decreased in both wild-type and mutant *EBP1*-overexpressing cells, but tamoxifen sensitivity was increased in combination with IPA only in wild-type transfectants. This finding would suggest that EBP1-induced changes in expression of additional proteins may have a role in the induction of tamoxifen sensitivity by IPA. For example, EBP1 decreases activity of the E2F1-regulated cell cycle gene Cyclin D1, which has a role in tamoxifen resistance ([@bib28]; [@bib2]). P21-activated kinase 1 is also an important regulator of Cyclin D1 expression ([@bib3]). It is possible that any reduction of PAK1 phosphorylation of endogenous EBP1 in the T261A mutant transfected cells is insufficient to alter Cyclin D1 levels and subsequently tamoxifen resistance, but adequate for altering ErbB2 protein levels.

In summary, we have found that PAK1--EBP1 interactions can increase tamoxifen sensitivity of hormone resistant breast cancer cells in part by EBP1\'s regulation of ErbB2 levels. An EBP1 phospho mimetic for a PAK1 site increased ErbB2 protein levels. IPA-3, a highly specific PAK1 inhibitor, abrogated tamoxifen-induced growth of hormone resistant cells and sensitised hormone resistant cells to tamoxifen in the presence of *EBP1* overexpression, accompanied by decreased ErbB2 expression. These studies suggest that strategies that increase the pool of functional EBP1 and decrease PAK1 activity may affect hormone resistant cell growth. Our results also suggest that PAK1 directed therapies may be more effective in patients that express high levels of EBP1.
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![**Effect of transfection of mutant *EBP1* on ErbB2 protein levels.** AU565 cells were transiently transfected with wild-type (WT) or mutant (T261E) *EBP1*. Two days later, lysates were collected and analysed by western blotting with antibodies to ErbB2, actin or GFP as indicated. Data are representative of three experiments.](bjc201311f1){#fig1}

![**An *EBP1* T261A mutant can reduce PAK1-induced tamoxifen resistance.** (**A**) MCF-7 cells were stably transfected with a constitutively active (T423E) *PAK1* vector. Cells were lysed and analysed by western blotting for expression of PAK1, ErbB2 or GAPDH as indicated. (**B**) Tamoxifen sensitivity of MCF-7 cells transfected with constitutively activated PAK1. MCF-7 cells stably transfected with a *PAK1* T423E expression vector or a vector control were incubated for 7 days in the presence of OHT at the indicated concentrations or vehicle control as described in the Materials and Methods. Viable cells were quantified using a Promega cell proliferation assay. Each data point represents the mean±s.d. of six wells. Similar results were observed in two independent experiments. ^\#^*P*\<0.01 vector controls *vs* PAK1-transfected cells. (**C)** Sensitivity of tamoxifen resistant MCF-7 *PAK1* T423E cells transfected with *EBP1* mutants to tamoxifen. MCF-7 cells stably transfected with a *PAK* T423E expression vector (see [Figure 2B](#fig2){ref-type="fig"}) were transiently transfected with GFP, GFP-*WT-EBP1*, GFP--*EBP1 T261A* or *GFP--EBP1 T261E* in complete media. Sixteen hours after transfection, cells were refed with media with the indicated concentrations of OHT. Growth was assessed 3 days later using a Promega cell proliferation assay as described in the Materials and Methods. Each data point represents the mean±s.d. of six wells. Similar results were observed in two independent experiments. ^\#^*P*\<0.01 *EBP1* T261A-transfected cells *vs* GFP-transfected cells at 2 *μ*ℳ OHT. Expression levels of the 80 kDa EBP1--GFP fusion proteins were measured by western blotting using a GFP antibody (inset).](bjc201311f2){#fig2}

![**A PAK inhibitor prevents tamoxifen-induced growth of PAK1-overexpressing hormone resistant cells.** (**A**) Hormone resistant cells overexpress PAK1. Lysates of logarithmically growing parental MCF-7 and LTLT-Ca cells were analysed by western blotting for total PAK1, pPAK or GAPDH as indicated. (**B**) Threonine phosphorylation of EBP1 in LTLT-Ca and MCF-7 cells. Lysates of logarithmically growing LTLT-Ca or MCF-7 cells were immunoprecipitated with either control IgG or EBP1 antibody before separation of proteins by SDS--PAGE. Proteins were transferred to PVDF membranes, and immunoblotted with antibodies to phospho threonine (pThr) or EBP1 as indicated. (**C**) LTLT-Ca cells were treated with IPA-3 at the indicated concentrations and cell number determined 7 days later as described in the Materials and Methods. ^\#^*P*\<0.01 compared with untreated control. (**D**) Effect of IPA-3 on PAK phosphorylation. Cells were serum starved overnight in media containing 0.5% FBS with or without 3 *μ*ℳ IPA-3 as indicated. Cells were then treated with 50 ng ml^−1^ of HRG for 60 min. Cell lysates were collected and analysed by western blotting for phospho PAK1 and total PAK1 as indicated. (**E**) LTLT-Ca cells were treated with the indicated concentrations of OHT with or without IPA-3 (3 *μ*ℳ) and cell number determined at day 7. Representative of five experiments. ^\#^*P*\<0.01 compared with untreated control.](bjc201311f3){#fig3}

![**IPA-3 reverses tamoxifen resistance when *EBP1* is overexpressed.** Expression of pPAK and PAK in control and *EBP1*-transfected LTLT-Ca cells. (**A**) LTLT-Ca vector control (EV) or *EBP1*-transfected cells were serum-starved overnight and treated with 50 ng ml^−1^ of HRG for 60 min. Cell lysates were analysed by western blotting for pPAK or total PAK1 as indicated. (**B**, **C**) LTLT-Ca cells stably transfected with wild-type *EBP1* (**B**) or *EBP1* T2621A (**C**) were treated with the indicated concentrations of OHT with or without IPA-3 (3 *μ*ℳ) and cell number determined at day 7 as described in the Materials and Methods. Representative of five experiments \**P*\<0.05 compared with untreated controls, ^\#^*P*\<0.01 compared with IPA only treated controls. (**D**) T47D EBP1-silenced cells were treated with the indicated concentrations of OHT with or without IPA-3 (3 *μ*ℳ) and cell number determined at day 7 as described in the Materials and Methods. Representative of two experiments.](bjc201311f4){#fig4}

![**Regulation of ErbB2 levels in LTLT-Ca cells by *EBP1* overexpression and IPA-3.** (**A**) ErbB2 expression levels were measured by western blot analysis of logarithmically growing vector control, *EBP1* wild-type or T261A-transfected LTLT-Ca cells. Expression of the GFP--EBP1 fusion protein and GAPDH was also analysed. (**B**) LTLT-Ca vector control or wild-type or mutant *EBP1*-transfected cells were serum-starved overnight in media containing 0.5% FBS with or without 3 *μ*ℳ IPA-3 as indicated. Cell lysates were collected and analysed by western blotting for ErbB2, GFP--EBP1, pMAPK, MAPK and GAPDH levels as indicated. The numbers below the ErbB2 western blot represent relative densities normalised to GAPDH. The numbers below the pMAPK blot indicate the relative densities of pMAPK normalised to MAPK (p44).](bjc201311f5){#fig5}
